Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Language
Year
  • 1
    Article
    Article
    Language: English
    In: Urology, October 2016, Vol.96, pp.73-73
    Keywords: Medicine
    ISSN: 0090-4295
    E-ISSN: 1527-9995
    Source: ScienceDirect Journals (Elsevier)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: German
    In: Der Urologe, 2016, Vol.55(5), pp.615-615
    Description: To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00120-016-0085-6 Byline: Maximilian Burger (1) Author Affiliation: (1) Klinik fur Urologie der Universitat Regensburg, Caritas-Krankenhaus, St. Josef, Landshuter Stra[sz]e 65, 93053, Regensburg, Deutschland Article History: Registration Date: 04/03/2016 Online Date: 27/04/2016
    Keywords: Cystectomy ; Urinary Bladder Neoplasms -- Surgery;
    ISSN: 0340-2592
    E-ISSN: 1433-0563
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: 2014, Vol.9(10), p.e109877
    Description: Clear cell renal cell carcinoma (ccRCC) characterized by a tumor thrombus (TT) extending into the inferior vena cava (IVC) generally indicates poor prognosis. Nevertheless, the risk for tumor recurrence after nephrectomy and thrombectomy varies. An applicable and accurate prediction system to select ccRCC patients with TT of the IVC (ccRCC/TT) at high risk after nephrectomy is urgently needed, but has not been established up to now. To our knowledge, a possible role of microRNAs (miRs) for the development of ccRCC/TT or their impact as prognostic markers in ccRCC/TT has not been explored yet. Therefore, we analyzed the expression of the previously described onco-miRs miR-200c, miR-210, miR-126, miR-221, let-7b, miR-21, miR-143 and miR-141 in a study collective of 74 ccRCC patients. Using the expression profiles of these eight miRs we developed classification systems that accurately differentiate ccRCC from non-cancerous renal tissue and ccRCC/TT from tumors without TT. In the subgroup of 37 ccRCC/TT cases we found that miR-21, miR-126, and miR-221 predicted cancer related death (CRD) accurately and independently from other clinico-pathological features. Furthermore, a combined risk score based on the expression of miR-21, miR-126 and miR-221 was developed and showed high sensitivity and specificity to predict cancer specific survival (CSS) in ccRCC/TT. Using the combined risk score we were able to classify ccRCC/TT patients correctly into high and low risk cases. The risk stratification by the combined risk score (CRS) will benefit from further cohort validation and might have potential for clinical application as a molecular prediction system to identify high- risk ccRCC/TT patients.
    Keywords: Research Article ; Medicine And Health Sciences
    E-ISSN: 1932-6203
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: German
    In: Aktuelle Urologie, 2015, Vol.46(03), pp.177-178
    Keywords: Bladder Exstrophy–Genetics ; Chromosomes, Human, Pair 5–Therapy ; Female–Genetics ; Genetic Markers–Genetics ; Humans–Genetics ; Infant, Newborn–Genetics ; Lim-Homeodomain Proteins–Genetics ; Male–Genetics ; Pregnancy–Genetics ; Transcription Factors–Genetics ; Genetic Markers ; Lim-Homeodomain Proteins ; Transcription Factors ; Insulin Gene Enhancer Binding Protein Isl-1;
    ISSN: 0001-7868
    E-ISSN: 1438-8820
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Scandinavian Journal of Urology, 04 May 2018, Vol.52(3), pp.199-199
    Keywords: Medicine
    ISSN: 2168-1805
    E-ISSN: 2168-1813
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Article
    Article
    Language: English
    In: European Urology Focus, July 2018, Vol.4(4), pp.468-469
    Description: While photodynamic diagnosis during transurethral resection of bladder tumor seems warranted only in seemingly high-risk cases, early intravesical instillation of chemotherapy is warranted in all low-risk cases. According to the latest randomized controlled trial, data may make sense also in intermediate- and high-risk cases.
    Keywords: Medicine
    ISSN: 2405-4569
    E-ISSN: 2405-4569
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Cancer, 01 March 2011, Vol.117(5), pp.938-47
    Description: The medical community lacks results from prospective controlled multicenter studies of the diagnostic efficacy of 5-aminolevulinic acid (5-ALA) cystoscopy on tumor recurrence in patients with superficial bladder tumors. A prospective randomized, double-blind, placebo-controlled study was conducted in 370 patients with nonmuscle-invasive urinary bladder carcinoma who received either 5-ALA (n = 187) or a placebo (n = 183) intravesically before cystoscopy. Each group underwent cystoscopy under visible white light and under fluorescent light followed by transurethral tumor resection. The primary study objective was to evaluate the 12-month recurrence-free survival. Slightly more patients with tumors were detected by using 5-ALA than by using the placebo (88.5% vs 84.7%). The mean numbers of tumor specimens per patient were 1.8 (5-ALA) and 1.6 (placebo). Intrapatient comparison of fluorescent light versus white light cystoscopy in patients randomized to receive 5-ALA showed a higher tumor detection rate with fluorescent light than with white light cystoscopy. In patients receiving 5-ALA cystoscopy, the percentage of lesions that would not have been detected in these patients by white light cystoscopy ranged between 10.9% (pT1) and 55.9% (atypia). Progression-free survival was 89.4% (5-ALA) and 89.0% (placebo) (P = .9101), and recurrence-free survival 12 months after tumor resection was 64.0% (5-ALA) and 72.8% (placebo) (P = .2216). In comparison to the placebo, 5-ALA cystoscopy did not increase the rates of recurrence-free or progression-free survival 12 months after tumor resection. Although more tumors per patient were detected in the 5-ALA group, the higher detection rate did not translate into differences in long-term outcome.
    Keywords: Aminolevulinic Acid ; Fluorescence ; Carcinoma -- Diagnosis ; Cystoscopy -- Methods ; Urinary Bladder Neoplasms -- Diagnosis
    ISSN: 0008-543X
    E-ISSN: 10970142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: BJU International, September 2012, Vol.110(5), pp.710-718
    Description: To purchase or authenticate to the full-text of this article, please visit this link: http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2011.10808.x/abstract Byline: Matthias Oelke(8), Maximilian Burger(1), David Castro-Diaz(2), Emmanuel Chartier-Kastler(3), Miguel A. Jimenez Cidre(4), Tom McNicholas(5), Piotr Radziszewski(6), Mike Kirby(7) Keywords: lower urinary tract symptoms (LUTS); treatment guidelines; storage symptoms; voiding symptoms; overactive bladder Study Type - Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Several sets of comprehensive treatment guidelines (national and international) exist for managing male lower urinary tract symptoms (LUTS), but these are not widely adopted in primary and secondary care, and are not consistently applied across Europe. This paper will improve the consistency of treatment approaches for adult males with LUTS by providing a clear, concise summary of existing treatment guidelines that can be easily adopted by urologists and primary care specialists. OBJECTIVE To review current treatment guidelines (international and national) on managing male lower urinary tract symptoms (LUTS) and to summarize them for easy application in clinical practice. METHODS A group of European urology specialists from primary and secondary care reviewed current treatment guidelines for male LUTS. RESULTS The most appropriate recommendations for managing male LUTS were identified from existing international and national guidelines, and were summarized and simplified for use as a quick reference guide for healthcare professionals managing LUTS in adult males. CONCLUSIONS Current guidelines for managing male LUTS were developed by urologists and are too complex for easy application in routine practice. This brief summary of current guidance should help to achieve consistent adoption of recommendations for best practice, improve working relationships between primary care specialists and urologists and clarify which patients' treatments should be managed entirely by urology specialists. Author Affiliation: (8)Hannover Medical School, Hannover, Germany, (1)University of Regensburg, Regensburg, Germany (2)Hospital Universitario de Canarias, Tenerife, Spain (3)Pitie-Salpetriere Hospital, Paris, France (4)Hospital Ramon y Cajal, Madrid, Spain (5)Lister Hospital, Stevenage, UK (6)Medical University of Warsaw, Warsaw, Poland (7)University of Hertfordshire, Hatfield, UK Correspondence: (*) Matthias Oelke, Department of Urology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hanover, Germany. e-mail: Oelke.Matthias@mh-hannover.de Accepted for publication 29 September 2011
    Keywords: Lower Urinary Tract Symptoms Luts ; Treatment Guidelines ; Storage Symptoms ; Voiding Symptoms ; Overactive Bladder
    ISSN: 1464-4096
    E-ISSN: 1464-410X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: The Journal of Urology, April 2013, Vol.189(4), pp.e389-e389
    Keywords: Medicine
    ISSN: 0022-5347
    E-ISSN: 1527-3792
    Source: ScienceDirect Journals (Elsevier)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: World Journal of Urology, 2014, Vol.32(4), pp.1041-1047
    Description: PURPOSETo evaluate the efficacy and safety of solifenacin for the treatment of OAB in men. METHODSThis prospective observational study, reflective of actual practice patterns, was conducted in men older than 18 years who were prescribed solifenacin for the treatment of OAB symptoms. Men with suspected bladder outlet obstruction were excluded. The primary efficacy measure was change in OAB symptoms after 12 weeks of solifenacin. Also assessed were changes in severity of urinary urgency, IPSS, quality of life, cognitive function, and adverse events. Data were analyzed using descriptive methods. RESULTSA total of 799 men recruited at 251 centers, average age 67 years (range 27-92), received solifenacin 5 mg or 10 mg/day. Mean episodes of urinary urgency, frequency, and nocturia decreased by 4.4, 3.6, and 1.4 episodes/24 h, respectively. As per IPSS, severe urinary symptoms were reported by 20.4 % at baseline versus by 2.3 % at week 12. Both voiding and storage symptoms showed improvement. Patient-reported general health condition was excellent/good for 39 % at baseline increasing to 76 % at week 12. Adverse event rate was 5.5 %, and discontinuation of solifenacin due to an event was 1.6 %. No change in post-void residual urine volume was experienced in 80%, while an increase of ≥50 mL was observed in 2.2 %; no cases of acute urinary retention occurred. Baseline mean MMSE was 27.5 points versus 27.9 points at week 12. CONCLUSIONSSolifenacin reduced all OAB symptoms, was well tolerated, and had no apparent effect on post-void residual urine volume. Cognitive function was unaltered in this population of older men with OAB.
    Keywords: Antimuscarinic ; Cognitive function ; Men ; Urinary retention
    ISSN: 0724-4983
    E-ISSN: 1433-8726
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages